Loading…
Anti-PD-1 antibodies / PD-1 inhibitors + Fecal Microbiota Transplantation (FMT) has shown some preliminary results in the treatment of Gastrointestinal cancers, particularly for patients who have developed resistance to anti-PD-1 therapy. This approach aims to enhance the efficacy of immunotherapy by modulating the gut microbiome.
A single-arm, open-label trial explored the efficacy of FMT combined with nivolumab in patients with anti-PD-1 resistant/refractory Gastrointestinal cancers
Peng et al. 2023 Journal of Clinical Oncology 41(4_suppl): JCO.2023.41.4_suppl
Another study focused on advanced Gastrointestinal cancers patients resistant to anti-PD-(L)1 treatment, reporting an objective response rate of 20% and a disease control rate of 40%. Two responders showed progression-free survival of 15 and more than 19 months, respectively.
A dose-escalation trial investigated different doses of Anti-PD-1 antibodies / PD-1 inhibitors + Fecal Microbiota Transplantation (FMT) in patients with advanced malignant solid tumors, including Gastrointestinal cancers
Zhu et al. 2024b Journal of Clinical Oncology 42(16 suppl): JCO.2024.42.16_suppl
see also:
Fecal Microbiota Transplantation (FMT) + Nivolumab & Melanoma (cutaneous)
Immune Checkpoint Inhibitors (ICIs) & Melanoma (cutaneous)
Gut microbiota & Immune Checkpoint Inhibitors (ICIs)
Crucial for future development of Fecal Microbiota Transplantation (FMT) in the context of Immune Checkpoint Inhibitors (ICIs) therapy, including selection of Fecal Microbiota Transplantation (FMT) donors, is to consider which bacteria are essential for a favorable response. Several bacterial species can be defined that are more abundant in responders (R) than in non-responders (NR).
Fecal Microbiota Transplantation (FMT) from HCC patients who received and responded to αPD-1 Ab treatment improved the efficacy of αPD-1 Ab treatment against HCC in mice model
Immune-checkpoint-inhibitor-associated colitis can be effectively treated using fecal microbiota transplantation. This treatment leads to the restoration of the gut microbiome and results in a relative increase in the proportion of regulatory T cells, within the colonic mucosa.
Fecal Microbiota Transplantation (FMT) from humans to mice confirmed that anti–CTLA-4 treatment of melanoma patients favored the outgrowth of B. fragilis with anticancer properties
Fecal Microbiota Transplantation (FMT) not only affects Intestinal immune cells but also leads to systemic Immune responses and, furthermore, to an influence on immune cells in the TME that have a beneficial effect on Immune Checkpoint Inhibitors (ICIs) Therapy
Modulating the gut microbiome of Immune Checkpoint Inhibitors (ICIs) Therapy- resistant cancer patients by Fecal Microbiota Transplantation (FMT) or by defined live bacterial products has shown potential in enhancing responses to Immune Checkpoint Inhibitors (ICIs) Therapy in cancer clinical trials
The Israeli trial () and one led by researchers in the United States () were the first of their kind to use Fecal Microbiota Transplantation (FMT) to prime patients for a better response to immunotherapies.
Today, at least 30 Fecal Microbiota Transplantation (FMT) trials are under way around the world, run by academic laboratories and pharmaceutical companies, with results beginning to trickle in
The Fecal Microbiota Transplantation (FMT) of Immune Checkpoint Inhibitors (ICIs)Therapy - responders favors the recruitment and activation of DCs and CD8 T cells. It has also induced the upregulation of Cxcl9 and Chemokine (C-X-C motif) ligand 10 (CXCL10) expression by epithelial cells, and the recruitment and expansion of CTLs in the colon
Fecal Microbiota Transplantation (FMT) with stool from donors who had responded to immunotherapy demonstrated the ability to promote response and overcome preexisting resistance to ICB therapy in melanoma
In Israel, a study is ongoing in which melanoma patients who failed anti-PD-1 therapy now receive an Fecal Microbiota Transplantation (FMT) (NCT03353402).
see also:
Anti-PD-1 antibodies / PD-1 inhibitors + Fecal Microbiota Transplantation (FMT) & Gastrointestinal cancers
Anti–PD-1 Resistance
Fecal Microbiota Transplantation (FMT) & Melanoma (cutaneous)
Fecal Microbiota Transplantation (FMT) (procedure-based) & Preclinical/Clinical data
Gut microbiota & Immune Checkpoint Inhibitors (ICIs)
Immune Checkpoint Inhibitors (ICIs) Therapy (to improve) & Drugs/Treatments
Immune Checkpoint Inhibitors (ICIs) & Melanoma (cutaneous)
Immune Checkpoint Inhibitors (ICIs) + Microbial Ecosystem Therapeutics 4 (MET-4) & Solid tumors
MET-4 + Pembrolizumab & Head and Neck Squamous Cell Carcinoma